NCT05128162View on ClinicalTrials.gov

Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 27, 2023

Primary Completion Date

June 12, 2024

Study Completion Date

June 12, 2024

Conditions
Fibromyalgia
Interventions
DRUG

Psilocybin

Two oral doses of psilocybin in a capsule formulation taken approximately 2 weeks apart.

BEHAVIORAL

Psychotherapy

1\. Pre-dose preparatory sessions; 2. Dosing day monitoring; and, 3. Post-dose integration sessions.

Trial Locations (1)

48106

Chronic Pain and Fatigue Research Center, Ann Arbor

All Listed Sponsors
lead

Kevin Boehnke

OTHER

NCT05128162 - Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia | Biotech Hunter | Biotech Hunter